Avanir grant
This article was originally published in The Tan Sheet
Executive Summary
NIH awards Avanir Pharmaceuticals a $100,000 Phase I Small Business Innovation Research grant to test docosonal with known antiviral agents, including acyclovir and other nucleoside antivirals. NIH issued the grant based on Avanir data indicating n-docosanol enhances the antiviral activity of nucleoside analogs against replication of several herpes viruses in vitro. Avanir says the funds will enable the firm to further study combination treatments to "provide more effective control of serious cases of herpes infections." Avanir's Abreva (docosonal 10%) cream is the first FDA-approved OTC for the treatment of cold sores and fever blisters (1"The Tan Sheet" July 31, p. 3). The firm had previously received one "not approvable" letter from FDA for the product, not two as reported in "The Tan Sheet"
You may also be interested in...
Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA
Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands